human apo transferrin Search Results


94
R&D Systems human apotransferrin
Figure 2 Hepatic differentiation of human ESCs and iPSCs transduced with three factors. (a) The procedure for differentiation of human ESCs and iPSCs into hepatocytes via DE cells and hepatoblasts is presented schematically. The hESF-DIF medium was supplemented with 10 μg/ml human recombinant insulin, 5 μg/ml human <t>apotransferrin,</t> 10 μmol/l 2-mercaptoethanol, 10 μmol/l ethanolamine, 10 μmol/l sodium selenite, and 0.5 mg/ml fatty-acid-free BSA. The L15 medium was supplemented with 8.3% tryptose phosphate broth, 8.3% FBS, 10 μmol/l hydrocortisone 21- hemisuccinate, 1 μmol/l insulin, and 25 mmol/l NaHCO3. (b) Sequential morphological changes (day 0–20) of human ESCs (H9) differentiated into hepatocytes via DE cells and hepatoblasts are shown. Red arrow shows the cells that have double nuclei. (c) The morphology of primary human hepatocytes is shown. Bar represents 50 μm. BSA, bovine serum albumin; DE, definitive endoderm; ESC, embryonic stem cell; iPSC, induced pluripotent stem cell.
Human Apotransferrin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+apo+transferrin/Human+Apo-Transferrin+Protein%2C+CF/pm22068426-151-65-85
Average 94 stars, based on 1 article reviews
human apotransferrin - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
R&D Systems apo transferrin
Figure 2 Hepatic differentiation of human ESCs and iPSCs transduced with three factors. (a) The procedure for differentiation of human ESCs and iPSCs into hepatocytes via DE cells and hepatoblasts is presented schematically. The hESF-DIF medium was supplemented with 10 μg/ml human recombinant insulin, 5 μg/ml human <t>apotransferrin,</t> 10 μmol/l 2-mercaptoethanol, 10 μmol/l ethanolamine, 10 μmol/l sodium selenite, and 0.5 mg/ml fatty-acid-free BSA. The L15 medium was supplemented with 8.3% tryptose phosphate broth, 8.3% FBS, 10 μmol/l hydrocortisone 21- hemisuccinate, 1 μmol/l insulin, and 25 mmol/l NaHCO3. (b) Sequential morphological changes (day 0–20) of human ESCs (H9) differentiated into hepatocytes via DE cells and hepatoblasts are shown. Red arrow shows the cells that have double nuclei. (c) The morphology of primary human hepatocytes is shown. Bar represents 50 μm. BSA, bovine serum albumin; DE, definitive endoderm; ESC, embryonic stem cell; iPSC, induced pluripotent stem cell.
Apo Transferrin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+apo+transferrin/Human+Apo-Transferrin+Protein%2C+CF/pm40541174-235-15-17
Average 94 stars, based on 1 article reviews
apo transferrin - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
Lee Biosolutions apotransferrin
Figure 2 Hepatic differentiation of human ESCs and iPSCs transduced with three factors. (a) The procedure for differentiation of human ESCs and iPSCs into hepatocytes via DE cells and hepatoblasts is presented schematically. The hESF-DIF medium was supplemented with 10 μg/ml human recombinant insulin, 5 μg/ml human <t>apotransferrin,</t> 10 μmol/l 2-mercaptoethanol, 10 μmol/l ethanolamine, 10 μmol/l sodium selenite, and 0.5 mg/ml fatty-acid-free BSA. The L15 medium was supplemented with 8.3% tryptose phosphate broth, 8.3% FBS, 10 μmol/l hydrocortisone 21- hemisuccinate, 1 μmol/l insulin, and 25 mmol/l NaHCO3. (b) Sequential morphological changes (day 0–20) of human ESCs (H9) differentiated into hepatocytes via DE cells and hepatoblasts are shown. Red arrow shows the cells that have double nuclei. (c) The morphology of primary human hepatocytes is shown. Bar represents 50 μm. BSA, bovine serum albumin; DE, definitive endoderm; ESC, embryonic stem cell; iPSC, induced pluripotent stem cell.
Apotransferrin, supplied by Lee Biosolutions, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+apo+transferrin/Apo+Transferrin%2C+Human+Serum+-+Iron+Free/10__26717_slash_bjstr__2019__13__002402-48-3-12
Average 92 stars, based on 1 article reviews
apotransferrin - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

90
Merck & Co human apo-transferrin
<t>Transferrin</t> protects RGCs in iron-treated retinal explants. ( A ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 1 mM FeSO 4 or transferrin (TF) (50 mg/mL) combined with FeSO 4 and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( B ) Brn3a-positive cells were counted, showing that TF significantly protects against the loss of RGCs from iron overload. ( C ) LDH released by explants during 3 h to 24 h of culture was significantly increased in presence of 1 mM FeSO 4 but absent in additive presence of TF. Data represent means ± SEM, n = 8–9 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns: not significant; ## p < 0.01; ### p < 0.001; #### p < 0.0001 compared to control; * p < 0.05; **** p < 0.0001; compared to stress condition. Scale bar: 100 µm.
Human Apo Transferrin, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+apo+transferrin/transferrin/pmc09659282-153-0-4
Average 90 stars, based on 1 article reviews
human apo-transferrin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Merck KGaA apo-transferrin
<t>Transferrin</t> protects RGCs in iron-treated retinal explants. ( A ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 1 mM FeSO 4 or transferrin (TF) (50 mg/mL) combined with FeSO 4 and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( B ) Brn3a-positive cells were counted, showing that TF significantly protects against the loss of RGCs from iron overload. ( C ) LDH released by explants during 3 h to 24 h of culture was significantly increased in presence of 1 mM FeSO 4 but absent in additive presence of TF. Data represent means ± SEM, n = 8–9 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns: not significant; ## p < 0.01; ### p < 0.001; #### p < 0.0001 compared to control; * p < 0.05; **** p < 0.0001; compared to stress condition. Scale bar: 100 µm.
Apo Transferrin, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+apo+transferrin/human+apo+transferrin/pmc08416315-75-0-61
Average 90 stars, based on 1 article reviews
apo-transferrin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Merck & Co human apo-transferrin (tf; >98% protein; ≤0.005% fe; cat. no. t1147)
<t>Transferrin</t> protects RGCs in iron-treated retinal explants. ( A ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 1 mM FeSO 4 or transferrin (TF) (50 mg/mL) combined with FeSO 4 and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( B ) Brn3a-positive cells were counted, showing that TF significantly protects against the loss of RGCs from iron overload. ( C ) LDH released by explants during 3 h to 24 h of culture was significantly increased in presence of 1 mM FeSO 4 but absent in additive presence of TF. Data represent means ± SEM, n = 8–9 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns: not significant; ## p < 0.01; ### p < 0.001; #### p < 0.0001 compared to control; * p < 0.05; **** p < 0.0001; compared to stress condition. Scale bar: 100 µm.
Human Apo Transferrin (Tf; >98% Protein; ≤0.005% Fe; Cat. No. T1147), supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+apo+transferrin/t1147/10__3389_slash_fchbi__2024__1394645-69-8-5
Average 90 stars, based on 1 article reviews
human apo-transferrin (tf; >98% protein; ≤0.005% fe; cat. no. t1147) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Boehringer Mannheim human transferrin apo-f
<t>Transferrin</t> protects RGCs in iron-treated retinal explants. ( A ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 1 mM FeSO 4 or transferrin (TF) (50 mg/mL) combined with FeSO 4 and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( B ) Brn3a-positive cells were counted, showing that TF significantly protects against the loss of RGCs from iron overload. ( C ) LDH released by explants during 3 h to 24 h of culture was significantly increased in presence of 1 mM FeSO 4 but absent in additive presence of TF. Data represent means ± SEM, n = 8–9 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns: not significant; ## p < 0.01; ### p < 0.001; #### p < 0.0001 compared to control; * p < 0.05; **** p < 0.0001; compared to stress condition. Scale bar: 100 µm.
Human Transferrin Apo F, supplied by Boehringer Mannheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+apo+transferrin/human+transferrin+apo+f/pm16109763-41-51-57
Average 90 stars, based on 1 article reviews
human transferrin apo-f - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Fluka Chemical human serum apo-transferrin
<t>Transferrin</t> protects RGCs in iron-treated retinal explants. ( A ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 1 mM FeSO 4 or transferrin (TF) (50 mg/mL) combined with FeSO 4 and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( B ) Brn3a-positive cells were counted, showing that TF significantly protects against the loss of RGCs from iron overload. ( C ) LDH released by explants during 3 h to 24 h of culture was significantly increased in presence of 1 mM FeSO 4 but absent in additive presence of TF. Data represent means ± SEM, n = 8–9 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns: not significant; ## p < 0.01; ### p < 0.001; #### p < 0.0001 compared to control; * p < 0.05; **** p < 0.0001; compared to stress condition. Scale bar: 100 µm.
Human Serum Apo Transferrin, supplied by Fluka Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+apo+transferrin/human+serum+apo+transferrin/pm19114286-38-11-25
Average 90 stars, based on 1 article reviews
human serum apo-transferrin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

N/A
Apo-Human transferrin (suitable for cell culture) refers to iron free Transferrin (HY-P3267), serves as Transferrin receptor ligand and mediates iron release from endothelial cells. Apo-Transferrin indicates an iron deficient environment, can directly bind to hephaestin,
  Buy from Supplier


N/A
Apo Transferrin Human; 1 gram
  Buy from Supplier

Image Search Results


Figure 2 Hepatic differentiation of human ESCs and iPSCs transduced with three factors. (a) The procedure for differentiation of human ESCs and iPSCs into hepatocytes via DE cells and hepatoblasts is presented schematically. The hESF-DIF medium was supplemented with 10 μg/ml human recombinant insulin, 5 μg/ml human apotransferrin, 10 μmol/l 2-mercaptoethanol, 10 μmol/l ethanolamine, 10 μmol/l sodium selenite, and 0.5 mg/ml fatty-acid-free BSA. The L15 medium was supplemented with 8.3% tryptose phosphate broth, 8.3% FBS, 10 μmol/l hydrocortisone 21- hemisuccinate, 1 μmol/l insulin, and 25 mmol/l NaHCO3. (b) Sequential morphological changes (day 0–20) of human ESCs (H9) differentiated into hepatocytes via DE cells and hepatoblasts are shown. Red arrow shows the cells that have double nuclei. (c) The morphology of primary human hepatocytes is shown. Bar represents 50 μm. BSA, bovine serum albumin; DE, definitive endoderm; ESC, embryonic stem cell; iPSC, induced pluripotent stem cell.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Article Title: Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4α transduction.

doi: 10.1038/mt.2011.234

Figure Lengend Snippet: Figure 2 Hepatic differentiation of human ESCs and iPSCs transduced with three factors. (a) The procedure for differentiation of human ESCs and iPSCs into hepatocytes via DE cells and hepatoblasts is presented schematically. The hESF-DIF medium was supplemented with 10 μg/ml human recombinant insulin, 5 μg/ml human apotransferrin, 10 μmol/l 2-mercaptoethanol, 10 μmol/l ethanolamine, 10 μmol/l sodium selenite, and 0.5 mg/ml fatty-acid-free BSA. The L15 medium was supplemented with 8.3% tryptose phosphate broth, 8.3% FBS, 10 μmol/l hydrocortisone 21- hemisuccinate, 1 μmol/l insulin, and 25 mmol/l NaHCO3. (b) Sequential morphological changes (day 0–20) of human ESCs (H9) differentiated into hepatocytes via DE cells and hepatoblasts are shown. Red arrow shows the cells that have double nuclei. (c) The morphology of primary human hepatocytes is shown. Bar represents 50 μm. BSA, bovine serum albumin; DE, definitive endoderm; ESC, embryonic stem cell; iPSC, induced pluripotent stem cell.

Article Snippet: The differentiation protocol for the induction of DE cells, hepatoblasts, and hepatocytes was based on our previous report with some modifications.7 Briefly, in mesendoderm differentiation, human ESCs and iPSCs were dissociated into single cells and cultured for 3 days on Matrigel (Becton, Dickinson and Company, Tokyo, Japan) in hESF-DIF medium (Cell Science & Technology Institute) supplemented with 10 g/ ml human recombinant insulin, 5 g/ml human apotransferrin, 10 mol/l 2-mercaptoethanol, 10 mol/l ethanolamine, 10 mol/l sodium selenite, 0.5 mg/ml BSA, and 100 ng/ml Activin A (R&D Systems, Minneapolis, MN).

Techniques: Transduction, Recombinant

Transferrin protects RGCs in iron-treated retinal explants. ( A ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 1 mM FeSO 4 or transferrin (TF) (50 mg/mL) combined with FeSO 4 and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( B ) Brn3a-positive cells were counted, showing that TF significantly protects against the loss of RGCs from iron overload. ( C ) LDH released by explants during 3 h to 24 h of culture was significantly increased in presence of 1 mM FeSO 4 but absent in additive presence of TF. Data represent means ± SEM, n = 8–9 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns: not significant; ## p < 0.01; ### p < 0.001; #### p < 0.0001 compared to control; * p < 0.05; **** p < 0.0001; compared to stress condition. Scale bar: 100 µm.

Journal: International Journal of Molecular Sciences

Article Title: Neuroprotective Effects of Transferrin in Experimental Glaucoma Models

doi: 10.3390/ijms232112753

Figure Lengend Snippet: Transferrin protects RGCs in iron-treated retinal explants. ( A ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 1 mM FeSO 4 or transferrin (TF) (50 mg/mL) combined with FeSO 4 and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( B ) Brn3a-positive cells were counted, showing that TF significantly protects against the loss of RGCs from iron overload. ( C ) LDH released by explants during 3 h to 24 h of culture was significantly increased in presence of 1 mM FeSO 4 but absent in additive presence of TF. Data represent means ± SEM, n = 8–9 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns: not significant; ## p < 0.01; ### p < 0.001; #### p < 0.0001 compared to control; * p < 0.05; **** p < 0.0001; compared to stress condition. Scale bar: 100 µm.

Article Snippet: Human apo-transferrin (50 mg/mL; Merck) was added to the culture medium during stress-induction and left for the whole culture period (96 h).

Techniques: Immunostaining, Incubation, Cell Culture

Transferrin protects RGCs in NMDA- or CoCl 2 -treated retinal explants. ( A ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 100 µM NMDA or TF (50 mg/mL) combined with NMDA and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( B ) Brn3a-positive cells were counted showing that TF significantly protects RGCs against NMDA-induced cell death. ( C ) LDH released by explants during 3 h to 24 h of culture was significantly increased in presence of 100 µM NMDA and absent in additive presence of TF. ( D ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 100 µM CoCl 2 or TF (50 mg/mL) combined with CoCl 2 and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( E ) Brn3a-positive cells were counted showing that TF significantly protects RGCs against CoCl 2 -induced cell death. ( F ) LDH released by explants during 3 h to 24 h of culturing was significantly increased in presence of 100 µM CoCl 2 and absent in additive presence of TF. Data represent means ± SEM, n = 6–10 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns: not significant; # p < 0.05; ## p < 0.01; #### p < 0.0001 compared to control. ns, not significant; * p < 0.05 ** p < 0.01; *** p < 0.001; compared to stress condition. Scale bar: 100 µm.

Journal: International Journal of Molecular Sciences

Article Title: Neuroprotective Effects of Transferrin in Experimental Glaucoma Models

doi: 10.3390/ijms232112753

Figure Lengend Snippet: Transferrin protects RGCs in NMDA- or CoCl 2 -treated retinal explants. ( A ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 100 µM NMDA or TF (50 mg/mL) combined with NMDA and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( B ) Brn3a-positive cells were counted showing that TF significantly protects RGCs against NMDA-induced cell death. ( C ) LDH released by explants during 3 h to 24 h of culture was significantly increased in presence of 100 µM NMDA and absent in additive presence of TF. ( D ) Representative images of retinal whole-mounts prepared for Brn3a immunostaining following 24 h incubation with 100 µM CoCl 2 or TF (50 mg/mL) combined with CoCl 2 and further cultured for 72 h (96 h total) in presence or not of TF. Untreated explant served as control. ( E ) Brn3a-positive cells were counted showing that TF significantly protects RGCs against CoCl 2 -induced cell death. ( F ) LDH released by explants during 3 h to 24 h of culturing was significantly increased in presence of 100 µM CoCl 2 and absent in additive presence of TF. Data represent means ± SEM, n = 6–10 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns: not significant; # p < 0.05; ## p < 0.01; #### p < 0.0001 compared to control. ns, not significant; * p < 0.05 ** p < 0.01; *** p < 0.001; compared to stress condition. Scale bar: 100 µm.

Article Snippet: Human apo-transferrin (50 mg/mL; Merck) was added to the culture medium during stress-induction and left for the whole culture period (96 h).

Techniques: Immunostaining, Incubation, Cell Culture

Transferrin protects RGCs against different cell-death mechanisms. Activation of apoptosis, necrosis, or ferroptosis in rat retinal explants exposed to FeSO 4 ( A ), NMDA ( B ) or CoCl 2 ( C ) in presence or in absence of TF was monitored by, respectively, the quantification of TUNEL-positive RGCs and by the change in RIP3 or GPX4 immunostaining intensity in RGC layer compared to controls (fold change). ( A ) FeSO 4 induces a significant increase in RIP3 and GPX4 expression which was limited or prevented by co-treatment with TF. ( B ) NMDA increases the number of TUNEL-positive cells as well as RIP3 and GPX4 expression. TF prevents increase in all three markers. ( C ) CoCl 2 induces a significant increase in the number of TUNEL-positive cells which was prevented by TF. Data represent means ± SEM, n = 4–10 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns, not significant; # p < 0.05; ## p < 0.01; ### p < 0.001; #### p < 0.0001 compared to control. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 compared to stress condition.

Journal: International Journal of Molecular Sciences

Article Title: Neuroprotective Effects of Transferrin in Experimental Glaucoma Models

doi: 10.3390/ijms232112753

Figure Lengend Snippet: Transferrin protects RGCs against different cell-death mechanisms. Activation of apoptosis, necrosis, or ferroptosis in rat retinal explants exposed to FeSO 4 ( A ), NMDA ( B ) or CoCl 2 ( C ) in presence or in absence of TF was monitored by, respectively, the quantification of TUNEL-positive RGCs and by the change in RIP3 or GPX4 immunostaining intensity in RGC layer compared to controls (fold change). ( A ) FeSO 4 induces a significant increase in RIP3 and GPX4 expression which was limited or prevented by co-treatment with TF. ( B ) NMDA increases the number of TUNEL-positive cells as well as RIP3 and GPX4 expression. TF prevents increase in all three markers. ( C ) CoCl 2 induces a significant increase in the number of TUNEL-positive cells which was prevented by TF. Data represent means ± SEM, n = 4–10 explants per condition. Statistical analysis was performed with Kruskal–Wallis and Dunn’s tests for multiple comparisons. ns, not significant; # p < 0.05; ## p < 0.01; ### p < 0.001; #### p < 0.0001 compared to control. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 compared to stress condition.

Article Snippet: Human apo-transferrin (50 mg/mL; Merck) was added to the culture medium during stress-induction and left for the whole culture period (96 h).

Techniques: Activation Assay, TUNEL Assay, Immunostaining, Expressing

Transferrin prevents retinal ganglion cell death and axon loss in rats exposed to ocular hypertension. ( A ) Rats were injected with microbeads in the anterior chamber on day 0. IOP remained significantly elevated over the four-week period of the study beginning at 48 h after OHT when compared to normotensive naïve animals. IOPs were not statistically different in vehicle- and TF-treated groups. ( B ) Representative micrographs of flat-mounted retina sections labeled for the RGC marker RBPMS. ( C ) Mean RGC density per mm 2 in the vehicle group was significantly reduced when compared with control animals (naïve group). TF significantly preserved RGC. ( D ) Axon density in optic nerves from vehicle-treated group was significantly lower than naïve. There was no difference in axon density between the TF treatment and naïve optic nerves. Data represent means ± SEM, n = 10 per group. Statistics are one-way ANOVA followed by Tukey’s multiple comparisons test. Symbols above the bars are comparisons with naïve control group. ns, not significant; #### p < 0.0001 compared to naïve control group. ** p < 0.01; *** p < 0.001 compared to vehicle-treated group.

Journal: International Journal of Molecular Sciences

Article Title: Neuroprotective Effects of Transferrin in Experimental Glaucoma Models

doi: 10.3390/ijms232112753

Figure Lengend Snippet: Transferrin prevents retinal ganglion cell death and axon loss in rats exposed to ocular hypertension. ( A ) Rats were injected with microbeads in the anterior chamber on day 0. IOP remained significantly elevated over the four-week period of the study beginning at 48 h after OHT when compared to normotensive naïve animals. IOPs were not statistically different in vehicle- and TF-treated groups. ( B ) Representative micrographs of flat-mounted retina sections labeled for the RGC marker RBPMS. ( C ) Mean RGC density per mm 2 in the vehicle group was significantly reduced when compared with control animals (naïve group). TF significantly preserved RGC. ( D ) Axon density in optic nerves from vehicle-treated group was significantly lower than naïve. There was no difference in axon density between the TF treatment and naïve optic nerves. Data represent means ± SEM, n = 10 per group. Statistics are one-way ANOVA followed by Tukey’s multiple comparisons test. Symbols above the bars are comparisons with naïve control group. ns, not significant; #### p < 0.0001 compared to naïve control group. ** p < 0.01; *** p < 0.001 compared to vehicle-treated group.

Article Snippet: Human apo-transferrin (50 mg/mL; Merck) was added to the culture medium during stress-induction and left for the whole culture period (96 h).

Techniques: Injection, Labeling, Marker